Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...
Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...
Arising from: Marks JB (2008) How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? Nat Clin Pract ...
Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is gen ...
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 - August 31, 2025. The report is available on the company's website: ...
Determined to "live as a healthy father," I administered my first injection of the lowest dose (2.5 mg) of the weight loss ...
Zacks Investment Research on MSN
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback